Hong DS, Cappuzzo F, Chul Cho B, Dowlati A, et al. Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer 2024;190:107512.
PMID: 38417277